Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 1;161(8):bqaa093.
doi: 10.1210/endocr/bqaa093.

A Role for GLP-1 in Treating Hyperphagia and Obesity

Affiliations
Free PMC article
Review

A Role for GLP-1 in Treating Hyperphagia and Obesity

Harvey J Grill. Endocrinology. .
Free PMC article

Abstract

Obesity is a chronic recurring disease whose prevalence has almost tripled over the past 40 years. In individuals with obesity, there is significant increased risk of morbidity and mortality, along with decreased quality of life. Increased obesity prevalence results, at least partly, from the increased global food supply that provides ubiquitous access to tasty, energy-dense foods. These hedonic foods and the nonfood cues that through association become reward predictive cues activate brain appetitive control circuits that drive hyperphagia and weight gain by enhancing food-seeking, motivation, and reward. Behavioral therapy (diet and lifestyle modifications) is the recommended initial treatment for obesity, yet it often fails to achieve meaningful weight loss. Furthermore, those who lose weight regain it over time through biological regulation. The need to effectively treat the pathophysiology of obesity thus centers on biologically based approaches such as bariatric surgery and more recently developed drug therapies. This review highlights neurobiological aspects relevant to obesity causation and treatment by emphasizing the common aspects of the feeding-inhibitory effects of multiple signals. We focus on glucagon like peptide-1 receptor (GLP-1R) signaling as a promising obesity treatment target by discussing the activation of intestinal- and brain-derived GLP-1 and GLP-1R expressing central nervous system circuits resulting from normal eating, bariatric surgery, and GLP-1R agonist drug therapy. Given the increased availability of energy-dense foods and frequent encounters with cues that drive hyperphagia, this review also describes how bariatric surgery and GLP-1R agonist therapies influence food reward and the motivational drive to overeat.

Keywords: GIP; PYY3-36; anatomically distributed neural control of food intake; appetitive behavior; endogenous controls of food intake inhibition; hedonic energy dense foods; increased food supply; nucleus tractus solitarius; reward predictive cues; satiation signals; striatum; vagal afferent transmission; visceral malaise.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Ogden CL, Carroll MD.. Prevalence of overweight, obesity, and extreme obesity among adults: United States, Trends 1960–1962 Through 2007–2008, in Division of Health and Nutrition Examination Surveys; CDCs National Center for Health Statistics; 2010:1-6.
    1. Hales CM, et al. . Prevalence of obesity and severe obesity among adults: United States 2017–2018, in NCHS Data Brief, no 360; 2020. - PubMed
    1. Bray GA, Kim KK, Wilding JPH; World Obesity Federation Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715-723. - PubMed
    1. Ward ZJ, Bleich SN, Cradock AL, et al. . Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. - PubMed
    1. Cefalu WT, Bray GA, Home PD, et al. . Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38(8):1567-1582. - PMC - PubMed

Publication types

Substances